Login Register Cart 0
Generic placeholder image

Current Drug Metabolism

Editor-in-Chief

ISSN (Print): 1389-2002
ISSN (Online): 1875-5453

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Effect of Aging on Deferasirox Therapy in Transfusion-dependent Patients. A Prospective- Retrospective, Cohort-study

Author(s): Valeria Marini, Valeria Maria Pinto, Manuela Stella, Carmen Fucile, Francesca Lantieri, Giacomo Luci, Barbara Gianesin, Lorenzo Bacigalupo, Gian Luca Forni and Francesca Mattioli*

Volume 23, Issue 13, 2022

Published on: 26 December, 2022

Page: [1072 - 1079] Pages: 8

DOI: 10.2174/1389200224666221209144420

Price: $65

Abstract

Background: Iron-chelation therapy is life-saving in patients on a chronic transfusion regimen as it reduces organ damage related to iron deposition in the tissues. Deferasirox, an iron-chelator, is characterized by pharmacokinetics variability, and some patients may discontinue the treatment due to toxicities.

Objective: Understanding whether deferasirox plasma levels are related to patients' specific characteristics could help to optimize DFX dosage.

Methods: We analyzed deferasirox plasma concentration in 57 transfusion-dependent anemic patients using the HPLC method in this prospective-retrospective cohort study. All outpatients (3 to 98 years) were treated with deferasirox (film-coated tablet) for at least one year (median dose, 16.5 mg/Kg once a day). Deferasirox plasma concentration was normalized for dose/Kg (C/dose) and corrected with a linear regression model that relates C/dose and the time of blood sampling (Cref/dose).

Results: No significant differences in Cref/dose were found between males and females, either between different types of hemoglobinopathies or depending on the presence of the UGT1A1*28 polymorphism. Cref/dose has a positive and significant correlation with age, creatinine, and direct bilirubin. Cref/dose, instead, has a negative and significant correlation with Liver Iron Concentration (LIC), ferritin, and eGFR. Cref/dose was significantly different between three age categories <18yrs, 18-50yrs, and >50yrs, with Cref/dose median values of 1.0, 1.2, and 1.5, respectively.

Conclusion: The study evidenced that to ensure the efficacy of deferasirox in terms of control over LIC and, at the same time, a lesser influence on renal function, the dose of the drug to be administered to an elderly patient could be reduced.

« Previous Next »
[1]
Taher, A.; Saliba, A.N.; Harb, A. Iron chelation therapy in transfusion-dependent thalassemia patients: Current strategies and future directions. J. Blood Med., 2015, 6, 197-209.
[http://dx.doi.org/10.2147/JBM.S72463] [PMID: 26124688]
[2]
Ballas, S.K. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin. Hematol., 2001, 38(Suppl. 1), 30-36.
[http://dx.doi.org/10.1053/shem.2001.20142] [PMID: 11206959]
[3]
Temraz, S.; Santini, V.; Musallam, K.; Taher, A. Iron overload and chelation therapy in myelodysplastic syndromes. Crit. Rev. Oncol. Hematol., 2014, 91(1), 64-73.
[http://dx.doi.org/10.1016/j.critrevonc.2014.01.006] [PMID: 24529413]
[4]
Gabutti, V.; Piga, A. Results of long-term iron-chelating therapy. Acta Haematol., 1996, 95(1), 26-36.
[http://dx.doi.org/10.1159/000203853] [PMID: 8604584]
[5]
Barton, J.C. Chelation therapy for iron overload. Curr. Gastroenterol. Rep., 2007, 9(1), 74-82.
[http://dx.doi.org/10.1007/s11894-008-0024-9] [PMID: 17335681]
[6]
Taher, A.T.; Saliba, A.N. Iron overload in thalassemia: Different organs at different rates. Hematology, 2017, 2017(1), 265-271.
[http://dx.doi.org/10.1182/asheducation-2017.1.265] [PMID: 29222265]
[7]
Hoffbrand, A.V.; Taher, A.; Cappellini, M.D. How I treat transfusional iron overload. Blood, 2012, 120(18), 3657-3669.
[http://dx.doi.org/10.1182/blood-2012-05-370098] [PMID: 22919029]
[8]
Ballas, S.K.; Zeidan, A.M.; Duong, V.H.; DeVeaux, M.; Heeney, M.M. The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review. Am. J. Hematol., 2018, 93(7), 943-952.
[http://dx.doi.org/10.1002/ajh.25103] [PMID: 29635754]
[9]
Sheth, S. Strategies for managing transfusional iron overload. Curr. Opin. Hematol., 2019, 26(3), 139-144.
[http://dx.doi.org/10.1097/MOH.0000000000000499] [PMID: 30855336]
[10]
Kattamis, A.; Aydinok, Y.; Taher, A. Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes. Eur. J. Haematol., 2018, 101(3), 272-282.
[http://dx.doi.org/10.1111/ejh.13111] [PMID: 29904950]
[11]
Cappellini, M.D.; Cohen, A.; Piga, A.; Bejaoui, M.; Perrotta, S.; Agaoglu, L.; Aydinok, Y.; Kattamis, A.; Kilinc, Y.; Porter, J.; Capra, M.; Galanello, R.; Fattoum, S.; Drelichman, G.; Magnano, C.; Verissimo, M.; Athanassiou-Metaxa, M.; Giardina, P.; Kourakli-Symeonidis, A.; Janka-Schaub, G.; Coates, T.; Vermylen, C.; Olivieri, N.; Thuret, I.; Opitz, H.; Ressayre-Djaffer, C.; Marks, P.; Alberti, D. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood, 2006, 107(9), 3455-3462.
[http://dx.doi.org/10.1182/blood-2005-08-3430] [PMID: 16352812]
[12]
Porter, J.; Galanello, R.; Saglio, G.; Neufeld, E.J.; Vichinsky, E.; Cappellini, M.D.; Olivieri, N.; Piga, A.; Cunningham, M.J.; Soulières, D.; Gattermann, N.; Tchernia, G.; Maertens, J.; Giardina, P.; Kwiatkowski, J.; Quarta, G.; Jeng, M.; Forni, G.L.; Stadler, M.; Cario, H.; Debusscher, L.; Della Porta, M.; Cazzola, M.; Greenberg, P.; Alimena, G.; Rabault, B.; Gathmann, I.; Ford, J.M.; Alberti, D.; Rose, C. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-yr prospective study. Eur. J. Haematol., 2008, 80(2), 168-176.
[http://dx.doi.org/10.1111/j.1600-0609.2007.00985.x] [PMID: 18028431]
[13]
Kontoghiorghes, G.J. A new era in iron chelation therapy: The design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients. Hemoglobin, 2009, 33(5), 332-338.
[http://dx.doi.org/10.3109/03630260903217182] [PMID: 19814679]
[14]
Exjade. 2022. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/exjade
[15]
Tanaka, C. Clinical pharmacology of deferasirox. Clin. Pharmacokinet., 2014, 53(8), 679-694.
[http://dx.doi.org/10.1007/s40262-014-0151-4] [PMID: 24996374]
[16]
Taher, A.T.; Origa, R.; Perrotta, S.; Kourakli, A.; Ruffo, G.B.; Kattamis, A.; Goh, A.S.; Cortoos, A.; Huang, V.; Weill, M.; Merino Herranz, R.; Porter, J.B. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study. Am. J. Hematol., 2017, 92(5), 420-428.
[http://dx.doi.org/10.1002/ajh.24668] [PMID: 28142202]
[17]
Tinsley, S.M.; Hoehner-Cooper, C.M. Transitioning patients with iron overload from Exjade to Jadenu. J. Infus. Nurs., 2018, 41(3), 171-175.
[http://dx.doi.org/10.1097/NAN.0000000000000278] [PMID: 29659464]
[18]
Tartaglione, I.; Origa, R.; Kattamis, A.; Pfeilstöcker, M.; Gunes, S.; Crowe, S.; Fagan, N.; Vincenzi, B.; Ruffo, G.B. Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: Phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study. Exp. Hematol. Oncol., 2020, 9(1), 20.
[http://dx.doi.org/10.1186/s40164-020-00174-2] [PMID: 32793403]
[19]
Piolatto, A.; Berchialla, P.; Allegra, S.; De Francia, S.; Ferrero, G.B.; Piga, A.; Longo, F. Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring. Sci. Rep., 2021, 11(1), 12581.
[http://dx.doi.org/10.1038/s41598-021-91983-w] [PMID: 34131221]
[20]
Mattioli, F.; Puntoni, M.; Marini, V.; Fucile, C.; Milano, G.; Robbiano, L.; Perrotta, S.; Pinto, V.; Martelli, A.; Forni, G.L. Determination of deferasirox plasma concentrations: Do gender, physical and genetic differences affect chelation efficacy? Eur. J. Haematol., 2015, 94(4), 310-317.
[http://dx.doi.org/10.1111/ejh.12419] [PMID: 25081908]
[21]
Allegra, S.; De Francia, S.; Cusato, J.; Pirro, E.; Massano, D.; Piga, A.; D’Avolio, A. Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment. J. Pharm. Pharmacol., 2016, 68(11), 1417-1421.
[http://dx.doi.org/10.1111/jphp.12638] [PMID: 27672004]
[22]
Wood, J.C.; Enriquez, C.; Ghugre, N.; Tyzka, J.M.; Carson, S.; Nelson, M.D.; Coates, T.D. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood, 2005, 106(4), 1460-1465.
[http://dx.doi.org/10.1182/blood-2004-10-3982] [PMID: 15860670]
[23]
James, W.P.T. Research on obesity; Her Majesty’s Stationery Office, Press: London , 1976.
[24]
Rouan, M.C.; Marfil, F.; Mangoni, P.; Séchaud, R.; Humbert, H.; Maurer, G. Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection. J. Chromatogr., Biomed. Appl., 2001, 755(1-2), 203-213.
[http://dx.doi.org/10.1016/S0378-4347(01)00079-2] [PMID: 11393706]
[25]
Galeotti, L.; Ceccherini, F.; Fucile, C.; Marini, V.; Di Paolo, A.; Maximova, N.; Mattioli, F. Evaluation of pharmacokinetics and pharmacodynamics of deferasirox in pediatric patients. Pharmaceutics, 2021, 13(8), 1238.
[http://dx.doi.org/10.3390/pharmaceutics13081238] [PMID: 34452199]
[26]
Pilo, F.; Cilloni, D.; Della Porta, M.G.; Forni, G.L.; Piperno, A.; Santini, V.; Angelucci, E. Iron-mediated tissue damage in acquired ineffective erythropoiesis disease: It’s more a matter of burden or more of exposure to toxic iron form? Leuk. Res., 2022, 114, 106792.
[http://dx.doi.org/10.1016/j.leukres.2022.106792] [PMID: 35091283]
[27]
Cappellini, M.D.; Bejaoui, M.; Agaoglu, L.; Canatan, D.; Capra, M.; Cohen, A.; Drelichman, G.; Economou, M.; Fattoum, S.; Kattamis, A.; Kilinc, Y.; Perrotta, S.; Piga, A.; Porter, J.B.; Griffel, L.; Dong, V.; Clark, J.; Aydinok, Y. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: Efficacy and safety during 5 years’ follow-up. Blood, 2011, 118(4), 884-893.
[http://dx.doi.org/10.1182/blood-2010-11-316646] [PMID: 21628399]
[28]
Fucile, C.; Mattioli, F.; Marini, V.; Gregori, M.; Sonzogni, A.; Martelli, A.; Maximova, N. What is known about deferasirox chelation therapy in pediatric HSCT recipients: Two case reports of metabolic acidosis. Ther. Clin. Risk Manag., 2018, 14, 1649-1655.
[http://dx.doi.org/10.2147/TCRM.S170761] [PMID: 30237719]
[29]
Piga, A.; Galanello, R.; Forni, G.L.; Cappellini, M.D.; Origa, R.; Zappu, A.; Donato, G.; Bordone, E.; Lavagetto, A.; Zanaboni, L.; Sechaud, R.; Hewson, N.; Ford, J.M.; Opitz, H.; Alberti, D. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica, 2006, 91(7), 873-880.
[PMID: 16818273]
[30]
Maximova, N.; Gregori, M.; Simeone, R.; Sonzogni, A.; Boz, G.; Fucile, C.; Marini, V.; Martelli, A.; Mattioli, F. Safety and tolerability of deferasirox in pediatric hematopoietic stem cell transplant recipients: One facility’s five years’ experience of chelation treatment. Oncotarget, 2017, 8(38), 63177-63186.
[http://dx.doi.org/10.18632/oncotarget.18725] [PMID: 28968980]
[31]
Nafea, O.E.; Zakaria, M.; Hassan, T.; El Gebaly, S.M.; Salah, H.E. Subclinical nephrotoxicity in patients with beta-thalassemia: Role of urinary kidney injury molecule. Drug Chem. Toxicol., 2022, 45(1), 93-102.
[http://dx.doi.org/10.1080/01480545.2019.1660362] [PMID: 31905029]
[32]
Pinto, V.M.; Poggi, M.; Russo, R.; Giusti, A.; Forni, G.L. Management of the aging beta-thalassemia transfusion-dependent population-The Italian experience. Blood Rev., 2019, 38, 100594.
[http://dx.doi.org/10.1016/j.blre.2019.100594] [PMID: 31416718]
[33]
Coates, T.D. Iron overload in transfusion-dependent patients. Hematology, 2019, 2019(1), 337-344.
[http://dx.doi.org/10.1182/hematology.2019000036] [PMID: 31808901]
[34]
Angelucci, E.; Capasso, M.; Della Porta, M.G.; Forni, G.L.; Girelli, D.; Oliva, E.N.; Pilo, F.; Clavio, M.; Riva, M.; Pelizzari, A.; Niscola, P.; Cilloni, D.; Binotto, G.; Crisà, E.; Santini, V. A multicenter, italian trial of early iron chelation therapy with low dose deferasirox (Exjade®) in patients with low/intermediate-1 risk MDS at the beginning of transfusional story. Blood, 2019, 134(Suppl. 1), 4256-4256.
[http://dx.doi.org/10.1182/blood-2019-125575]
[35]
Dou, H.; Qin, Y.; Chen, G.; Zhao, Y. Effectiveness and safety of deferasirox in Thalassemia with iron overload: A meta-analysis. Acta Haematol., 2019, 141(1), 32-42.
[http://dx.doi.org/10.1159/000494487] [PMID: 30504715]
[36]
Castagnola, E.; Cangemi, G.; Mesini, A.; Castellani, C.; Martelli, A.; Cattaneo, D.; Mattioli, F. Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: A narrative review. Int. J. Antimicrob. Agents, 2021, 58(3), 106381.
[http://dx.doi.org/10.1016/j.ijantimicag.2021.106381] [PMID: 34157401]
[37]
Marini, V.; Fucile, C.; Zuccoli, M.L.; Testino, G.; Sumberaz, A.; Robbiano, L.; Martelli, A.; Mattioli, F. Involvement of the mu-opioid receptor gene polymorphism A118G in the efficacy of detoxification of alcohol dependent patients. Addict. Behav., 2013, 38(3), 1669-1671.
[http://dx.doi.org/10.1016/j.addbeh.2012.09.015] [PMID: 23254216]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy